Evidence map›Paper›PMID 20209733›Full record

ArticleCanadian journal of public health = Revue canadienne de sante publique

Use and reimbursement costs of smoking cessation medication under the Quebec public drug insurance plan.

Michèle Tremblay, Yves Payette, Annie Montreuil

Abstract read
In one paragraph

Article in Canadian journal of public health = Revue canadienne de sante publique. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Smoking restrictions in homes after implementation of a smoking ban in public places.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2015
    Article
  2. Article
  3. Use of smoking cessation products: A survey of patients in community pharmacies.Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Michèle TremblayInstitut national de santé publique du Québec, Montreal, QC. michele.tremblay@inspq.qc.ca
Yves Payette
Annie Montreuil

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesSince October 2000, the nicotine patch, nicotine gum and bupropion have been reimbursed under Quebec's public drug insurance plan. The objective of this study is to describe use of these medications between October 2000 and December 2004 by smokers covered by the public plan, as well as the costs of reimbursing these medications.

methodsData from the Régie de l'assurance maladie du Québec were used to analyze prescriptions for smoking cessation medication issued to persons insured under the public drug insurance plan.

resultsBetween October 1, 2000, and December 31, 2004, more than 300,000 Quebeckers covered by the public drug insurance plan were reimbursed for smoking cessation medications. This corresponds to a yearly average of 14% of all smokers insured under the public plan. The proportion of employment assistance recipients who used these medications was higher than the proportion of seniors or "other" insurance plan participants. Nicotine patches were the treatment of choice for most users. A total of $55 million was reimbursed by the public drug insurance plan for the nicotine patch, nicotine gum and bupropion over this four-year period.

conclusionThe reimbursement provisions put in place in Quebec in 2000 were successful in reaching financially disadvantaged smokers, at a cost that was comparable with other effective smoking cessation services.

Indexed as

Insurance, Health, ReimbursementAdolescentAdultFemaleHumansMaleMiddle AgedPublic HealthQuebecSmoking CessationTobacco Use DisorderYoung Adult

Identifiers

PMID20209733
PMCPMC6973766

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.